NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $2.4B; returns 1 day -8.7%, 1 week -0.6%, 1 year -45.7%.

NewAmsterdam Pharma (NAMS) is a late-stage biopharmaceutical company focused on developing oral therapies for cardiovascular disease, with its lead candidate obicetrapib, a CETP inhibitor designed to lower LDL cholesterol. The company has no commercial revenue as of January 2026, operating as a clinical-stage entity funded by cash reserves from prior financings and partnerships.

Groups NAMS belongs to

• Biotechnology
• Biopharmaceutical
• Cardiovascular Therapies
• Clinical Stage Biotech
• LDL Cholesterol Reduction
• Clinical Stage
• Healthcare
• Life Sciences
• R&D

NAMS financial model: income statement, cash flow and balance sheet